Serum glycated albumin predicts all-cause mortality in dialysis patients with diabetes mellitus: meta-analysis and syste
- PDF / 1,700,750 Bytes
- 11 Pages / 595.276 x 790.866 pts Page_size
- 2 Downloads / 139 Views
ORIGINAL ARTICLE
Serum glycated albumin predicts all‑cause mortality in dialysis patients with diabetes mellitus: meta‑analysis and systematic review of a predictive biomarker Sidar Copur1 · Dimitrie Siriopol2 · Baris Afsar3 · Melis C. Comert1 · Gizem Uzunkopru1 · Alan A. Sag4 · Alberto Ortiz5 · Adrian Covic2 · Daniel H. van Raalte6 · David Z. Cherney7,8 · Peter Rossing9 · Mehmet Kanbay10 Received: 30 April 2020 / Accepted: 16 July 2020 © Springer-Verlag Italia S.r.l., part of Springer Nature 2020
Abstract Background and Aim HbA1c, the traditional and current gold standard biomarker guiding diabetic management, has been scrutinized for low predictive value for patients with chronic kidney disease due to variables affecting erythrocyte number and turnover. Glycated albumin, the precursor to advanced glycation end products, reflects glycemic status over the preceding 2–3 week period and already outperforms HbA1c for glycemic monitoring. Our aim was to establish whether serum GA can be further used to predict mortality risk in dialysis patients with diabetes mellitus (DM) Methods We did systematic review of the literature in PubMed/Medline, Web of Science, Embase (Elsevier) and the Cochrane Central Register of Controlled Trials (Wiley) up to and including February 2020. Results This meta-analysis included 25,932 dialysis patients across 12 studies with maximum follow-up of 11 years. Higher GA levels were associated with the risk of all-cause mortality in dialysis patients with DM (HR 1.02, 95% CI 1.01 to 1.03, P
Data Loading...
